-- フェルミ（FRMI）は月曜日、筆頭独立取締役のマリウス・ハース氏を会長に任命したと発表した。就任は即日発効となる。 同社はまた、最高経営責任者（CEO）兼共同創業者であるトビー・ノイゲバウアー氏がCEOを辞任したが、取締役会には留任すると発表した。 移行期間中は、複数のメンバーで構成される新たなCEO室が運営リーダーシップチームとして機能すると同社は述べた。 フェルミは、取締役会が次期CEOの選任に向けた正式な選考プロセスを開始したと発表した。 同社はまた、取締役として留任するマイルズ・エバーソン氏の辞任に伴い、暫定最高財務責任者（CFO）の候補者と交渉中であると付け加えた。 同社の株価は月曜日のプレマーケット取引で20%以上下落した。
Price: $5.19, Change: $-1.36, Percent Change: -20.76%
Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.
Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07
Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.